Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
Category: #health  By Pankaj Singh  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
  • The Phase 1 clinical trial assessing RBN-2397 will be the first clinical evaluation of monoPARP Inhibitor.
     
  • RBN-2397 is the company’s PARP7 inhibitor and is capable of potently inhibiting cancer cell proliferation.

Ribon Therapeutics, a biotech company involved in the development of cutting-edge therapeutics that targets novel enzyme families that are activated by cellular stress conditions, recently announced that it dosed the first patient in a Phase 1 clinical trial that assesses RBN-2397, which is its first-in-class PARP7 inhibitor.

Apparently, PARP7 belongs to an enzyme family that gets activated by cellular stress conditions, called the monoPARPs, that are different from polyPARPs like PARP1/2. New research pioneer by Ribon has exhibited that monoPARPs as the main regulators of responses to stress and have been linked to the formation of diseases like cancer.

Chief Medical Officer at Ribon Therapeutics, Sudha Parasuraman, M.D., said that the company is aiming to target PARP7 with the help of RBN-2397, PARP7 plays an important role in the survival of cancer cells. Inhibiting PARP7 has the ability to potently inhibit the proliferation of cancer cells as well as release a ‘brake’ which the cancer cells utilize to evade the immune system.

Parasuraman further continued that the company has seen a strong preclinical evidence that supports RBN-2397’s clinical potential and also believes that the inhibitor could prove to be a valuable treatment option for patients suffering from cancer.  

Chief Executive Officer and President at Ribon Therapeutics, Victoria Richon, Ph.D., said that bringing in the company’s lead compound in the clinic is a major milestone for Ribon and it demonstrates the company’s ability to advance the program initiation into a clinic within three years. The progress shown by Ribon validates the efficiency and utility of the company’s platform which has rapidly been involved in the development of clinical drug candidates and interrogation of novel biological pathways.

Richon further added, the platform has a wide potential application that enables the company to develop top-of-the-line therapeutics to fight an increasing set of targets in neurodegeneration, inflammatory disease and oncology.

 

Source Credit- https://ribontx.com/ribon-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-rbn-2397-a-first-in-class-parp7-inhibitor/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Early data from first human CRISPR trials reveals promising results
Early data from first human CRISPR trials reveals promising results
By Pankaj Singh

Vertex Pharmaceuticals and CRISPR Therapeutics have recently revealed early data from their joint trials to test CRISPR treatment in humans. The data was obtained from two patients suffering from serious blood disorder...

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
By Pankaj Singh

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection frac...

Nike to halt direct sale of its shoes and clothes through Amazon
Nike to halt direct sale of its shoes and clothes through Amazon
By Pankaj Singh

In efforts to retain their relevance in the continuously evolving world of ecommerce, companies are losing the personal touch they once had with their customers. Lately however, prominent brands that have a well-establ...